Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Nat Commun
Main Authors: He, Yundong, Peng, Shihong, Wang, Jinhua, Chen, Huang, Cong, Xiaonan, Chen, Ang, Hu, Meichun, Qin, Min, Wu, Haigang, Gao, Shuman, Wang, Liguo, Wang, Xin, Yi, Zhengfang, Liu, Mingyao
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5159881/
https://ncbi.nlm.nih.gov/pubmed/27959342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13122
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker